{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:40:22Z","timestamp":1697427622091},"reference-count":10,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,3,23]],"date-time":"2004-03-23T00:00:00Z","timestamp":1080000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the effect of duloxetine on the pharmacokinetics and tolerability of tolterodine and its active 5\u2010hydroxymethyl metabolite (5\u2010HM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixteen healthy subjects received two 5\u2010day treatment regimens in a randomized, double\u2010blinded, crossover fashion: tolterodine (2\u2003mg, BID) +\u200aduloxetine (40\u2003mg, BID), tolterodine (2\u2003mg, BID) +\u200aduloxetine placebo (BID). Plasma concentrations of tolterodine and 5\u2010HM were measured on day 5. Adverse events, clinical safety laboratory data and vital signs were assessed during the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Duloxetine increased the AUC<jats:sub>\u03c4,ss<\/jats:sub> of tolterodine by 71%[geometric mean, 95% confidence interval (CI) 31, 123], and its <jats:italic>C<\/jats:italic><jats:sub>max,ss<\/jats:sub> by 64% (CI 30, 106), and prolonged its <jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub> by 14% (CI 1, 28). Duloxetine did not affect the plasma concentrations or <jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub> of 5\u2010HM. Laboratory data and vital signs did not reveal any clinically significant changes or abnormalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Duloxetine exhibited minor inhibitory effects on the pharmacokinetics of tolterodine but not 5\u2010HM. Coadministration of these drugs was well tolerated and demonstrated no significant safety findings in the studied population. These findings suggest that there should not be a need for routine adjustment of tolterodine dosage in the presence of duloxetine.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2004.02068.x","type":"journal-article","created":{"date-parts":[[2004,12,20]],"date-time":"2004-12-20T20:42:42Z","timestamp":1103575362000},"page":"652-656","source":"Crossref","is-referenced-by-count":17,"title":["Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers"],"prefix":"10.1111","volume":"57","author":[{"given":"Teng C.","family":"Hua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clark","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeo K.","family":"Poo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary P.","family":"Knadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celedon R.","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,3,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.1993.4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.124840"},{"key":"e_1_2_6_4_2","first-page":"106","article-title":"Duloxetine for the treatment of major depressive disorder","volume":"36","author":"Nemeroff CB","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00501.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00717.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.108171"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90104-7"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.28"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00051.x"},{"key":"e_1_2_6_11_2","volume-title":"Detrol\u00ae, tolterodine tartrate","year":"2000"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2004.02068.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2004.02068.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:16:51Z","timestamp":1697426211000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2004.02068.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,23]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1111\/j.1365-2125.2004.02068.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02068.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,23]]}}}